A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Study on the Use of Rho-Kinase Inhibitor to Reduce Ore Prevent Proliferative Vitreoretinopathy (PVR) in Eyes With Rhegmatogenous Retinal Detachment (RRD) at High Risk of PVR
Latest Information Update: 01 Aug 2024
At a glance
- Drugs Netarsudil (Primary) ; Glycerol; Hypromellose; Polyethylene glycol
- Indications Proliferative vitreoretinopathy; Retinal detachment
- Focus Therapeutic Use
Most Recent Events
- 30 Jul 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 30 Jul 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 30 Jul 2024 Status changed from recruiting to active, no longer recruiting.